| Patient | Alan Turing |
|---|---|
| Date of birth | 1912-06-23 |
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
| Document date | 1953-08-04 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Sixteen-week review of hormone recovery and depression treatment. [S]
Mr. Turing returns eight weeks after starting bupropion XL 150 mg. The nurse telephone check planned for two weeks after the start did not happen: he was abroad at a conference, two calls went unanswered, and no further call was booked. He had a dry mouth and some difficulty falling asleep in the first week, which settled when he took the tablet earlier in the morning, and no headache, tremor, or restlessness. He has missed no doses. His mood is clearly better: he enjoys running again, at about 35 km a week, and has started working on a new problem with real pleasure. He sleeps about seven hours. Libido and erections are back to his usual. He has had fourteen psychotherapy sessions. The breast tissue is smaller and tender only when pressed. He has had no suicidal thoughts. [S]
| Element | Detail |
|---|---|
| Missed contact | Two-week nurse call after starting bupropion not completed |
| Bupropion | Dry mouth and trouble falling asleep in week one, now settled; no missed doses |
| Sexual function | Libido and erections back to his usual |
| Running | About 35 km a week |
| Safety | No suicidal thoughts |
| PHQ-9 | 7, down from 15 |
| System | Result | Finding |
|---|---|---|
| Breast | Negative | Tender only when pressed; no discharge |
| Neurological | Negative | No headache, tremor, or seizures |
| Cardiovascular | Negative | No palpitations |
| Psychiatric | Positive | Mild residual low mood on some days; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
| Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1953-06-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-08-04 | Body height | 178 | cm | S |
| 1953-08-04 | Body weight | 69.3 | kg | S |
| 1953-08-04 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1953-08-04 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1953-08-04 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1953-08-04 | Heart rate | 60 | /min | S |
| 1953-08-04 | Respiratory rate | 14 | /min | S |
| 1953-08-04 | Body temperature | 36.7 | Cel | S |
| 1953-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1953-08-04 | Testosterone [Mass/volume] in Serum or Plasma | 452 | ng/dL | 264-916 ng/dL | Normal | S |
| 1953-08-04 | Lutropin [Units/volume] in Serum or Plasma | 4.8 | m[IU]/mL | 1.7-8.6 m[IU]/mL | Normal | S |
| 1953-08-04 | Follitropin [Units/volume] in Serum or Plasma | 5.2 | m[IU]/mL | 1.5-12.4 m[IU]/mL | Normal | S |
| 1953-08-04 | Hemoglobin [Mass/volume] in Blood | 14.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
Vital signs recorded on 1953-08-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; brisk |
| Breast | Examined with his agreement: glandular tissue about 2.5 cm behind the left nipple and 1.5 cm behind the right, tender only on firm pressure; no discrete mass |
| Mental status | Alert; mood "much more like myself"; affect reactive with humor; thought process linear; no suicidal ideation; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | resolved | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | Glandular tissue about 2.5 cm on the left and 1.5 cm on the right, tender only on firm pressure; no discrete mass |
| Laboratory | Testosterone, LH, and FSH | Every 6 to 8 weeks after the exposure stops, until normal | Completed today | Testosterone 452 ng/dL, LH 4.8 and FSH 5.2 mIU/mL: all normal; recovery complete |
| Laboratory | Hemoglobin while testosterone is low | With each hormone check until normal | Completed today | 14.4 g/dL |
| Imaging | Bone density (DXA) | If hypogonadism persists beyond six months or a fragility fracture occurs | Not indicated | The axis recovered within about four months of the last estrogen dose |
| Medication safety | Testosterone therapy | Only for persistent, symptomatic, confirmed testosterone deficiency | Not indicated | Not given while the axis recovers: it would suppress LH and FSH again and is not indicated for a transient, drug-induced low testosterone |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 7, down 53 percent from 15: response; remission not yet reached |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Safety plan reviewed |
| Medication safety | Antidepressant tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Deferred | Not done, a deviation from the protocol: the nurse telephone check two weeks after bupropion was started, which was also to supply the monthly PHQ-9, was not completed after two unanswered calls while he was abroad, and no further call was booked, leaving eight weeks without a score. No harm resulted judging by today's review: the early insomnia and dry mouth settled, blood pressure is 124/78 mmHg, and there were no suicidal thoughts. Corrective action: a missed safety call is now rebooked within two days and flagged to Dr. Hallam if it cannot be completed |
| Medication safety | Adherence, adverse effects, and blood pressure on bupropion | Every visit during active treatment | Completed today | No missed doses; early dry mouth and insomnia settled; blood pressure 124/78 mmHg |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Fourteen sessions; sleep about seven hours; running about 35 km a week |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |
Goal progress:
Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Six-month review in two months with testosterone, estradiol, vitamin D, and PHQ-9. Next scheduled visit 1953-10-06: six-month review of gynecomastia and depression in continuation treatment. [S]